EA201892083A1 - SUBSTITUTED MENIN-MLL INHIBITORS AND METHODS OF APPLICATION - Google Patents

SUBSTITUTED MENIN-MLL INHIBITORS AND METHODS OF APPLICATION

Info

Publication number
EA201892083A1
EA201892083A1 EA201892083A EA201892083A EA201892083A1 EA 201892083 A1 EA201892083 A1 EA 201892083A1 EA 201892083 A EA201892083 A EA 201892083A EA 201892083 A EA201892083 A EA 201892083A EA 201892083 A1 EA201892083 A1 EA 201892083A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
menin
substituted
application
mll
Prior art date
Application number
EA201892083A
Other languages
Russian (ru)
Other versions
EA038388B1 (en
Inventor
Тао Ву
Ляньшэн Ли
И Ван
Пингда Рен
Иоланта Грембека
Томаш Сирпики
Шимон Клоссовски
Джонатан Поллок
Дмитрий Боркин
Original Assignee
Кура Онколоджи, Инк.
Зе Реджентс Оф Зе Юниверсити Oф Мичиган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кура Онколоджи, Инк., Зе Реджентс Оф Зе Юниверсити Oф Мичиган filed Critical Кура Онколоджи, Инк.
Priority claimed from PCT/US2017/022564 external-priority patent/WO2017161028A1/en
Publication of EA201892083A1 publication Critical patent/EA201892083A1/en
Publication of EA038388B1 publication Critical patent/EA038388B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

Настоящее изобретение относится к способам ингибирования взаимодействия менина с MLL1, MLL2 и MLL-слитыми онкопротеинами. Данные способы применимы для лечения лейкоза, солидных типов рака, диабета и других заболеваний, зависящих от активности MLL1, MLL2, слитых белков MLL и/или менина. Настоящее изобретение также относится к композициям для применения в данных способах.The present invention relates to methods for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fused oncoproteins. These methods are applicable for the treatment of leukemia, solid types of cancer, diabetes and other diseases that depend on the activity of MLL1, MLL2, MLL fusion proteins and / or menin. The present invention also relates to compositions for use in these methods.

EA201892083A 2017-01-16 2017-03-15 Substituted inhibitors of menin-mll and methods of use EA038388B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762446640P 2017-01-16 2017-01-16
PCT/US2017/022564 WO2017161028A1 (en) 2016-03-16 2017-03-15 Substituted inhibitors of menin-mll and methods of use

Publications (2)

Publication Number Publication Date
EA201892083A1 true EA201892083A1 (en) 2019-04-30
EA038388B1 EA038388B1 (en) 2021-08-19

Family

ID=66436970

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892083A EA038388B1 (en) 2017-01-16 2017-03-15 Substituted inhibitors of menin-mll and methods of use

Country Status (1)

Country Link
EA (1) EA038388B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473054B1 (en) * 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
AR090037A1 (en) * 2011-11-15 2014-10-15 Xention Ltd DERIVATIVES OF TIENO AND / OR FURO-PYRIMIDINES AND PYRIDINES INHIBITORS OF THE POTASSIUM CHANNELS
US9216993B2 (en) * 2013-03-13 2015-12-22 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Also Published As

Publication number Publication date
EA038388B1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
EA201792583A1 (en) METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS
PH12018501952A1 (en) Substituted inhibitors of menin-mill and methods of use
PH12018501955A1 (en) Bridged bicyclic inhibitors of menin-mll and methods of use
CY1124834T1 (en) INHIBITORS OF THE MINE-MLL INTERACTION
MX2022013841A (en) Inhibitors of the menin-mll interaction.
EA202092590A1 (en) PYRIDAZINONES AS PARP7 INHIBITORS
MX2021010482A (en) Compounds and methods for the enhanced degradation of targeted proteins.
EA201791867A1 (en) BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
MX2018007703A (en) Inhibitors of the menin-mll interaction.
EA201890749A1 (en) ACETHYL-COA-CARBOXYLASE INHIBITORS (ACC) AND THEIR APPLICATION
EA201990187A1 (en) PYRIMIDINE ANTIPROLIFERATION AGENTS
EA201791775A1 (en) CYTESTINE PROTEASIS
EA201791866A1 (en) BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EA202191852A1 (en) IRREVERSIBLE INHIBITORS OF THE MENIN-MLL INTERACTION
EA201592005A1 (en) BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EA201991214A1 (en) ANTIBODIES AGAINST PD-1 AND THEIR COMPOSITION
MX2015011576A (en) Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof.
EA201791773A1 (en) CYTESTINE PROTEASIS
EA201890158A1 (en) ANTIBODIES AGAINST NTB-A AND RELATED COMPOSITIONS AND METHODS
EA202090204A1 (en) ANTI-CD137 ANTIBODIES
SA519410093B1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
EA201792262A1 (en) PIROGLUTAMAT VORTIOKSETINA
UA117933C2 (en) Stable polypeptides binding to human complement c5
EA201591421A1 (en) DRUGS OF POLYPEPTIDE FACTOR IX
EA201792380A1 (en) NEW EPHA4 INHIBITORS AIMED AT HIS LIGAND-BINDING DOMAIN